Evidence map›Paper›PMID 42746080›Full record

ArticleAdvances in hematology2026

Real-World Outcomes of Hypomethylating Agents for Higher-Risk Myelodysplastic Syndromes: Report From the Nationwide Multicenter Thai MDS Study.

Theerin Lanamtieng, Chantana Polprasert, Pimjai Niparuck, Phatsorn Choksomnuk, Thanawat Rattanathammethee, Wasithep Limvorapitak, Kannadit Prayongratana, Rattapan Lamool, Archrob Khuhapinant, Weerapat Owattanapanich and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Theerin LanamtiengDivision of Hematology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, kku.ac.th.ORCID https://orcid.org/0000-0001-6690-3024
Chantana PolprasertDivision of Hematology, Department of Medicine and Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, chula.ac.th.ORCID https://orcid.org/0000-0001-6949-4449
Pimjai NiparuckDivision of Hematology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th.
Phatsorn ChoksomnukDivision of Hematology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th.
Thanawat RattanathammetheeDivision of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, cmu.ac.th.ORCID https://orcid.org/0000-0003-2731-4889
Wasithep LimvorapitakDivision of Hematology, Department of Medicine, Thammasat University, Pathumthani, Thailand, tu.ac.th.ORCID https://orcid.org/0000-0003-1451-7636
Kannadit PrayongratanaDivision of Hematology, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand, pmk.ac.th.ORCID https://orcid.org/0000-0003-3447-7600
Rattapan LamoolDivision of Hematology, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand, pmk.ac.th.ORCID https://orcid.org/0000-0002-8990-3462
Archrob KhuhapinantDivision of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th.
Weerapat OwattanapanichDivision of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th.ORCID https://orcid.org/0000-0002-1262-2005
Pisa PhiphitapornDivision of Hematology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, kku.ac.th.ORCID https://orcid.org/0009-0007-1540-9086
Kanchana ChansungDivision of Hematology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, kku.ac.th.
Suporn ChuncharuneeDivision of Hematology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, mahidol.ac.th.ORCID https://orcid.org/0000-0002-0028-9620

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypomethylating agents (HMAs) are the standard of care for higher-risk myelodysplastic syndromes (MDSs); however, their accessibility remains limited. This retrospective multicenter cohort study aimed to evaluate the real-world overall survival (OS) of HMAs compared to best-available treatments (BATs) in newly diagnosed higher-risk MDS in Thailand. Higher-risk MDS was defined by a Revised International Prognostic Scoring System (IPSS-R) score > 3.5. Data were extracted from the MDS registry of multicenter hospitals in Thailand from 2013 to 2023. Patients who underwent hematopoietic stem cell transplantation were excluded. A total of 155 patients were included, with a median age of 70 years and a male predominance. The median follow-up time was 36 months. Of these, 86 patients (55.5%) received BATs, while 69 patients (44.5%) were treated with HMAs. HMAs were found to significantly improve OS compared to BATs (log-rank test:

Indexed as

clinical outcomehypomethylating agentsmyelodysplastic syndromesurvival

Identifiers

PMID42746080
PMCPMC13575782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.